Orbimed Advisors Llc Decreased Insys Therapeutics Inc New (NASDAQ:INSY) Stake By $11.37 Million

May 23, 2018 - By Marie Mckinney

Investors sentiment decreased to 0.76 in 2017 Q4. Its down 0.49, from 1.25 in 2017Q3. It turned negative, as 21 investors sold INSY shares while 29 reduced holdings. 20 funds opened positions while 18 raised stakes. 16.43 million shares or 9.75% less from 18.21 million shares in 2017Q3 were reported. Susquehanna Group Limited Liability Partnership invested in 119,608 shares or 0% of the stock. Bnp Paribas Arbitrage stated it has 14,833 shares. State Of Wisconsin Board has invested 0% in INSYS Therapeutics, Inc. (NASDAQ:INSY). Sei Company has 6 shares for 0% of their portfolio. Hightower Advsrs Lc accumulated 22,378 shares. Mirae Asset Global Investments Co Ltd reported 1.47 million shares or 0.19% of all its holdings. Stone Ridge Asset Limited Company reported 14,227 shares or 0.01% of all its holdings. Virtu Fincl Ltd Liability Corp holds 0.01% or 20,061 shares in its portfolio. Bessemer Gp stated it has 50 shares or 0% of all its holdings. Wells Fargo Mn invested in 0% or 57,020 shares. Manufacturers Life Ins The reported 23,332 shares or 0% of all its holdings. Benjamin F Edwards holds 340 shares or 0% of its portfolio. Wealthtrust reported 200 shares. Macquarie holds 0% or 1,200 shares. Perigon Wealth Management Ltd accumulated 0% or 57 shares.

Since February 21, 2018, it had 0 buys, and 1 insider sale for $1.07 million activity.

Samuel Isaly decreased its stake in Insys Therapeutics Inc New (NASDAQ:INSY) by 35.05% based on its latest 2018Q1 regulatory filing with the SEC. Orbimed Advisors Llc sold 1.90M shares as the company’s stock declined 18.40% with the market. The hedge fund run by Samuel Isaly held 3.51 million shares of the health care company at the end of 2018Q1, valued at $21.21 million, down from 5.41M at the end of the previous reported quarter. Orbimed Advisors Llc who had been investing in Insys Therapeutics Inc New for a number of months, seems to be less bullish one the $529.95M market cap company. The stock increased 7.97% or $0.53 during the last trading session, reaching $7.18. About 925,779 shares traded or 59.90% up from the average. INSYS Therapeutics, Inc. (NASDAQ:INSY) has declined 45.03% since May 23, 2017 and is downtrending. It has underperformed by 56.58% the S&P500.

Orbimed Advisors Llc, which manages about $6.70 billion and $8.07 billion US Long portfolio, upped its stake in Davita Inc (NYSE:DVA) by 1.08M shares to 1.56 million shares, valued at $102.84 million in 2018Q1, according to the filing. It also increased its holding in Alexion Pharmaceuticals Inc (NASDAQ:ALXN) by 388,700 shares in the quarter, for a total of 3.27 million shares, and has risen its stake in Insmed Inc (NASDAQ:INSM).

A very big health care fund, Sam Isaly’s Orbimed Advisors makes investments in companies at different levels from those in the public markets to venture capital. The fund main targets are businesses providing medical and pharmaceutical devices and not insurers or hospitals, or it could be said instead of services. Orbimed Advisors Llc is a New York-based hedge fund that was founded by Samuel Isaly. It had more than $6.70 billion assets under management in August, 2014. Taken from Orbimed Advisors latest Adv, the fund reported to have 72 full and part-time employees. Among which 58 performing investment advisory and research functions. The hedge fund had between 11-25 clients.

Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company has market cap of $529.95 million. The firm markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. It currently has negative earnings. It is also developing Cannabidiol Oral Solution, which has completed pediatric study for the treatment of pediatric epilepsy; has completed Phase II study to treat west syndrome; and is in Phase II study for the treatment of childhood absence epilepsy, as well as Buprenorphine Sublingual Spray that has completed Phase III study to treat acute pain.

More notable recent INSYS Therapeutics, Inc. (NASDAQ:INSY) news were published by: Seekingalpha.com which released: “A Buvaya Failure Could Sting Insys” on May 18, 2018, also Benzinga.com with their article: “The Week Ahead In Biotech: PDUFA Dates, IPOs And More” published on May 21, 2018, Fool.com published: “Better Marijuana Stock: Insys Pharmaceuticals vs. Cara Therapeutics” on May 19, 2018. More interesting news about INSYS Therapeutics, Inc. (NASDAQ:INSY) were released by: Nasdaq.com and their article: “Warren Buffett’s Mentor Was Right About the Crazy Market — and 2 Biotech Stocks Prove It” published on May 23, 2018 as well as Seekingalpha.com‘s news article titled: “Insys Earnings Preview” with publication date: May 08, 2018.

INSYS Therapeutics, Inc. (NASDAQ:INSY) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: